地尔硫(卓)对冠心病患者经皮冠状动脉介入治疗术后近期主要不良心血管事件的影响

摘要

Objective To detect the impact of Diltiazem on the major adverse cardiac events (MACE) in six months after percutaneous coronary intervention (PCI).Methods A total of 192 patients after PCI with coronary atherosclerotic heart disease were enrolled in this study.The patients were randomly divided into Diltiazem therapy group (101 patients) and non-Diltiazem therapy group (91 patients).The high-sensitivity C-reactive protein (hs-CRP) was assessed before and 24 h after PCI,and the incidence of Major adverse cardiovascular events(MACEs) were assessed at the sixth month after PCI.Results Compared with before PCI,hs-CRP level increased significantly in both group after PCI (P＜0.01),but hs-CRP level was lower in Diltiazem therapy group than in non-Diltiazem therapy group (P＜0.05).Compared with non-Diltiazem therapy group,there was lower incidence of MACEs during six months follow-up in Diltiazem therapy group.Conclusions Diltiazem can decrease the incidence of MACEs during six months after PCI.%目的 观察地尔硫(卓)对冠心病患者经皮冠状动脉介入治疗(PCI)术后6个月内主要不良心血管事件(MACE)的影响. 方法 冠心病PCI术后的患者192例,随机分为地尔硫(卓)治疗组(治疗组)101例和常规治疗组(对照组)91例,观察两组患者术前、术后24 h超敏C反应蛋白(hsCRP)的变化水平及6个月内MACE的发生. 结果 治疗组和对照组患者PCI术后hs-CRP分别为(6.59±1.45)mg/L、(8.37±1.82)mg/L,较术前(4.11±0.82) mg/L、(4.25±0.67) mg/L明显升高(t=14.962、20.265,均P=0.000),但与对照组比较,治疗组术后hs-CRP升高幅度较低(t=7.529,P=0.000);治疗组6个月内MACE的发生人数为9例,较对照组23例低,差异有统计学意义(x2 =9.229,P=0.002). 结论 PCI术后予以地尔硫(卓)治疗能降低6个月内MACE的发生.